Current filters:  
Asia Pacific
Life Sciences, Biotechnology & Nanotechnology
Davies Collison Cave
This newsletter contains helpful up-to-date resources for our clients.
McCullough Robertson
Digital clinical trials should be accompanied by attention to regulatory caveats, patient privacy and data protection.
Clyde & Co
The weekly briefings are prepared to assist you with keeping up to date with the effects of any legislative, regulatory or general changes as a consequence of Coronavirus (COVID-19).
Davies Collison Cave
This is our fifth publication of useful resources for our clients during the current coronavirus disruption.
Shelston IP
Regulatory arrangements in relation to the practice of biosimilar approval & substitution and concerns that have been raised.
Davies Collison Cave
In the current COVID-19 environment, much of the innovation that we will require to tackle this pandemic will be borrowed from innovations of the past.
Davies Collison Cave
Special measures have been passed in Australia which exempt specified treatments for COVID-19 from requirements to be registered on the Australian Register of Therapeutic Goods (ARTG) prior to their supply.
Corrs Chambers Westgarth
The issue of advertising and when it is misleading is important for the pharmaceutical and life sciences industries.
Arnold & Porter
China has proposed a new rule framing a drug patent linkage system that will have significant impact on multinational pharmaceutical companies doing business in China
Human genetic resources (HGR) have long been regulated in China under the Interim Measures for the Administration of HGR (人类遗传资源管理暂行办法) (Interim Measures)...
Arnold & Porter
Multinational pharmaceutical and medical device companies conducting clinical trials in China have been facing new challenges in the year since the Regulation on Human Genetic Resources...
Ropes & Gray LLP
China's State Council released the new Cosmetic Regulation (the "New Regulation") on June 16, 2020, which is a major overhaul of the current 30-year-old Cosmetic Regulation
Mayer Brown
On 30 April 2020, the National People's Congress of China (the "NPC") published the Biological Safety Law (Draft for Second Reading) (the "Draft Law") for public consultation until 13 June 20201.
創新医療機器特別審査制度の紹介 過日、医療機器の研究開発およびイノベーションを促進し、医療機器の新技術の普及および応用を推し๫
Hong Kong
Mayer Brown
This Legal Update follows up on our previous Legal Update.
HSA Advocates
Last year, in November 2019, a High- Level Committee (HLC) on Corporate Social Responsibility (CSR) was set up to review the CSR framework and make recommendations for developing a more robust...
Obhan & Associates
Corporate Social Responsibility (CSR) has been a soft law in most countries and is considered voluntary, self-regulated and beyond the scope of legislation.
Phoenix Legal
These hard corona times shall pass.
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Popular Contributors
Upcoming Events
Font Size:
Mondaq Social Media